Quick Answer
Adaptive Biotechnologies Corp reported Stockholders Equity of $218.79 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed an increase of +7.9% in Stockholders Equity from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$233.61 million | Q2 2018: -$242.44 million | Q3 2018: -$248.08 million | Q1 2019: -$273.47 million | Q2 2019: -$284.37 million | Q3 2019: $585.93 million | Q1 2020: $551.56 million | Q2 2020: $529.94 million | Q3 2020: $775.05 million | Q1 2021: $725.59 million | Q2 2021: $693.18 million | Q3 2021: $651.51 million | Q1 2022: $553.21 million | Q2 2022: $518.30 million | Q3 2022: $487.84 million | Q1 2023: $424.02 million | Q2 2023: $396.04 million | Q3 2023: $361.73 million | Q1 2024: $274.91 million | Q2 2024: $241.60 million | Q3 2024: $223.77 million | Q1 2025: $190.42 million | Q2 2025: $179.72 million | Q3 2025: $204.44 million.
- Over the full 10 years of available data (2016 to 2025), Adaptive Biotechnologies Corp's Stockholders Equity has grown by 215.3%.
- Historical annual values: Fiscal year 2025: $218.79 million | Fiscal year 2024: $202.71 million | Fiscal year 2023: $308.40 million | Fiscal year 2022: $464.17 million | Fiscal year 2021: $603.99 million | Fiscal year 2020: $743.27 million | Fiscal year 2019: $571.04 million | Fiscal year 2018: -$258.11 million | Fiscal year 2017: -$224.62 million | Fiscal year 2016: -$189.73 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: